Plasma ADMA associates with all-cause mortality in renal transplant recipients
Open Access
- 16 June 2015
- journal article
- clinical trial
- Published by Springer Nature in Amino Acids
- Vol. 47 (9) , 1941-1949
Abstract
Asymmetric dimethylarginine (ADMA) is a key endogenous inhibitor of endothelial NO synthase that affects endothelial function, blood pressure and vascular remodeling. Increased plasma levels of ADMA are associated with worse outcome from cardiovascular disease. Due to endothelial dysfunction before and after kidney transplantation, renal transplant recipients (RTR) are at high risk for the alleged deleterious effects of ADMA. We investigated the associations of ADMA levels with all-cause mortality and graft failure in RTR. Plasma ADMA levels were determined in 686 stable outpatient RTR (57 % male, 53 ± 13 years), with a functioning graft for ≥1 year. Determinants of ADMA were evaluated with multivariate linear regression models. Associations between ADMA and mortality were assessed using multivariable Cox regression analyses. The strongest associations with plasma ADMA in the multivariable analyses were male gender, donor age, parathyroid hormone, NT-pro-BNP and use of calcium supplements. During a median follow-up of 3.1 [2.7–3.9] years, 79 (12 %) patients died and 45 (7 %) patients developed graft failure. ADMA was associated with increased all-cause mortality [HR 1.52 (95 % CI 1.26–1.83] per SD increase, P < 0.001], whereby associations remained upon adjustment for confounders. ADMA was associated with graft failure [HR 1.41 (1.08–1.83) per SD increase, P = 0.01]; however, upon addition of eGFR significance was lost. High levels of plasma ADMA are associated with increased mortality in RTR. Our findings connect disturbed NO metabolism with patient survival after kidney transplantation.Keywords
This publication has 36 references indexed in Scilit:
- Asymmetric Dimethylarginine Enhances Cardiovascular Risk Prediction in Patients With Chronic Heart FailureArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- The Determinants of Endothelial Dysfunction in CKD: Oxidative Stress and Asymmetric DimethylarginineAmerican Journal of Kidney Diseases, 2006
- The DDAH-ADMA-NOS PathwayTherapeutic Drug Monitoring, 2005
- Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2005
- Asymmetric Dimethylarginine and Progression of Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2005
- Reduced Urinary Excretion of Nitric Oxide Metabolites and Increased Plasma Levels of Asymmetric Dimethylarginine in Men with Essential HypertensionJournal of Cardiovascular Pharmacology, 1999
- Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial DysfunctionCirculation, 1998
- Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthaseAmerican Journal of Physiology-Heart and Circulatory Physiology, 1995
- Hypertension in mice lacking the gene for endothelial nitric oxide synthaseNature, 1995
- Regional and cardiac haemodynamic effects of NG, NG,dimethyl‐l‐arginne and their reversibility by vasodilators in conscious ratsBritish Journal of Pharmacology, 1993